Directorate Change

RNS Number : 3020J

Avacta Group PLC

29 March 2018

 

29 March 2018

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Directorate Change

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, announces that Dr Michael Albin, one of the Group's Non-Executive Directors will be stepping down from the Board with effect from 30 March 2018.

Dr Alastair Smith, Group Chief Executive Officer, commented:

"I would like to thank Michael for his contribution to the Group over the last four years, his advice and support around the development of our Affimer technology has been invaluable. I am glad that Michael's association with Avacta will continue in an advisory capacity."

- Ends -

For further information from Avacta Group plc, please contact:

Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer	Tel:  [phone] www.avacta.com
finnCap Ltd Geoff Nash / Giles Rolls - Nominated Adviser Tim Redfern / Alice Lane / Nikita Jain - Corporate Broking WG Partners Nigel Birks / Nigel Barnes David Wilson / Claes Spang	Tel:  [phone] www.finncap.com Tel:  [phone] Tel:  [phone] www.wgpartners.co.uk
Zyme Communications (Trade and Regional Media) Katie Odgaard Yellow Jersey PR (Financial Media and IR) Sarah Hollins	Tel: [phone] [e-mail]  Tel: [phone] [e-mail]

To register for Avacta news alerts by email go to www.avacta.com/investor-news-email-alerts

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer^® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

 

END

 

 

BOALLFFEVTITFIT